Loading patent…
AssigneeResearch Foundation for Mental Hygeine, Inc.
InventorsKhalid Iqbal, Inge Grundke-Iqbal
Estimating the term…
The present invention is directed to methods for treating Alzheimer disease and other disorders associated with the presence of neurofibrillary tangles (NFTs) by increasing the activity of a phosphatase towards abnormal hyperphosphorylated tau (“AD P-tau”) present in the NFTs of paired helical filaments in the neurons of patients having Alzheimer disease or other NFT-associated disorder. Pharmaceutical compositions and diagnostic methods are also provided. The inventions provide methods of treatment by administering to a subject a therapeutically effective amount of a composition comprising a molecule which increases protein phosphatase activity toward AD P-tau, a phosphatase which dephosphorylates AD P-tau, or a nucleic acid encoding such a phosphatase.
A method of treating a subject having a disease or disorder associated with the presence of neurofibrillary tangles comprising administering to the subject a therapeutically effective amount of a composition comprising a molecule, which molecule increases the activity of at least one protein phosphatase towards abnormal hyperphosphorylated tau, which protein phosphatase is selected from the group consisting of PP-2A, PP-2B, PP-1, and related protein phosphatases.
A method of treating a subject having a disease or disorder associated with the presence of neurofibrillary tangles comprising administering to the subject a therapeutically effective amount of a composition comprising at least one protein phosphatase which dephosphorylates abnormal hyperphosphorylated tau, which protein phosphatase is selected from the group consisting of PP-2A, PP-2B, PP-1, and related protein phosphatases.
A method of treating a subject having a disease or disorder associated with the presence of neurofibrillary tangles comprising administering to the subject a therapeutically effective amount of a composition comprising a nucleic acid encoding a protein phosphatase which dephosphorylates abnormal hyperphosphorylated tau, which protein phosphatase is selected from the group consisting of PP-2A, PP-2B, PP-1, and related protein phosphatases.
A pharmaceutical composition comprising a therapeutically effective amount of a phosphatase which dephosphorylates abnormal hyperphosphorylated tau, and a pharmaceutically acceptable carrier;
A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a phosphatase which dephosphorylates abnormal hyperphosphorylated tau, and a pharmaceutically acceptable carrier;
A pharmaceutical composition comprising a therapeutically effective amount of a manganese ion, manganese salt, or manganese conjugate, in a slow-release formulation.
A method of diagnosing the presence in a subject of a disease or disorder associated with the presence of neurofibrillary tangles comprising:
Dependencies are inferred from the claim text.